도르졸라미드, 티몰롤 및 브리모니딘을 포함하는 안과용 액제 조성물
    11.
    发明授权
    도르졸라미드, 티몰롤 및 브리모니딘을 포함하는 안과용 액제 조성물 有权
    包含多瑙酰胺,槲皮酚和嘧啶酮的非线性液体组合物

    公开(公告)号:KR101119610B1

    公开(公告)日:2012-03-06

    申请号:KR1020100121718

    申请日:2010-12-02

    Abstract: PURPOSE: An ophthalmic liquid composition containing dorzolamide or salt thereof, timolol or salt thereof, and brimonidine of salt thereof is provided to minimize irritation and to ensure stability. CONSTITUTION: An ophthalmic liquid composition of surfactant-free and saccharide-free contains 1-3 w/v% of dorzolamide or salt thereof, 0.1-1 w/v% of timolol or salt thereof, 0.1-0.5 w/v% of brimonidine of salt thereof, 1.0-1.5 w/v% of polyvinyl pyrrolidone, 0.2-0.8 w/v% of sodium chloride, 0.3-0.6 w/v% of buffer, preservative, pH adjusting agent, and water.

    Abstract translation: 目的:提供含有多佐胺或其盐,噻吗洛尔或其盐及其溴莫尼啶的眼用液体组合物以使刺激最小化并确保稳定性。 构成:无表面活性剂和无糖的眼用液体组合物含有1-3w / v%的多佐胺或其盐,0.1-1w / v%的噻吗洛尔或其盐,0.1-0.5w / v%的溴莫尼定 的盐,1.0-1.5w / v%的聚乙烯吡咯烷酮,0.2-0.8w / v%的氯化钠,0.3-0.6w / v%的缓冲剂,防腐剂,pH调节剂和水。

    텔미사르탄-함유 정제의 제조방법
    13.
    发明公开
    텔미사르탄-함유 정제의 제조방법 审中-实审
    制备含替米沙坦的片剂的方法

    公开(公告)号:KR1020170095525A

    公开(公告)日:2017-08-23

    申请号:KR1020160017011

    申请日:2016-02-15

    Abstract: 본발명은습식과립법에의한텔미사르탄-함유정제의제조방법으로서, 흡착제로서콜로이드성이산화규소및 특정희석제를사용하는것을포함하는텔미사르탄-함유정제의제조방법을제공한다.

    Abstract translation: 本发明提供了通过湿法制粒来制备含替米沙坦的片剂的方法,该方法包括使用含有胶态二氧化硅的含替米沙坦的片剂作为吸附剂和特定的稀释剂。

    나노에멀젼 형태의 안과용 조성물
    19.
    发明公开
    나노에멀젼 형태의 안과용 조성물 有权
    NANOEMULSION形式中的OPALALMIC组成

    公开(公告)号:KR1020120075445A

    公开(公告)日:2012-07-06

    申请号:KR1020120048915

    申请日:2012-05-09

    CPC classification number: A61K38/13 A61K9/0048 B82Y5/00

    Abstract: PURPOSE: An opthalmic composition of a nano-emulsion type is provided to minimize the use of additives and to enhance stability. CONSTITUTION: An opthalmic composition of a nano-emulsion type with 200 nm or less or particle size contains cyclosporine A; 0.05-0.80 v/v% of propylene glycol dicaprylocaprate and medium chain triglyceride of 8-10 carbon atoms as oil; and 0.63-1.32 vv/v% of poly oxyl 35 hydrogenate castor oil as a surfactant in an aqueous medium.

    Abstract translation: 目的:提供纳米乳液型的组合物,以最小化添加剂的使用并提高稳定性。 构成:具有200nm以下或粒径的纳米乳液型的组合物含有环孢菌素A; 0.05-0.80v / v%的丙二醇二辛酸二辛酯和8-10个碳原子的中链甘油三酯作为油; 和0.63-1.32vv / v%的聚氧基35氢化蓖麻油作为水性介质中的表面活性剂。

Patent Agency Ranking